Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02437019 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia

Interventions

DRUG: PCI-32765 (Ibrutinib)

Sponsor

Janssen-Cilag Farmaceutica Ltda.